• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 13, 2020 at 12:22: PM
via Genentech, a Roche company, announced that the Phase III IMagyn050 trial of Tecentriq (atezolizumab) and Avastin (bevacizumab), paclitaxel and carboplatin did not hit the primary endpoint of progression-free survival (PFS) for frontline newly-diagnosed advanced ovarian cancer.

article source
 




Top Bottom
Back
Quote